MacroGenics Stock Forecast, Price & News

MacroGenics (NASDAQ:MGNX) Frequently Asked Questions

Is MacroGenics a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 1 sell rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MacroGenics stock.
View analyst ratings for MacroGenics or view top-rated stocks.

How has MacroGenics' stock price been impacted by Coronavirus (COVID-19)?

MacroGenics' stock was trading at $6.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MGNX shares have increased by 189.2% and is now trading at $18.77.
View which stocks have been most impacted by COVID-19.

When is MacroGenics' next earnings date?

MacroGenics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for MacroGenics.

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) released its quarterly earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.23. MacroGenics had a negative net margin of 126.03% and a negative trailing twelve-month return on equity of 46.52%. During the same quarter last year, the business earned ($0.66) EPS.
View MacroGenics' earnings history.

What price target have analysts set for MGNX?

8 brokers have issued 12-month price objectives for MacroGenics' shares. Their forecasts range from $17.00 to $41.00. On average, they anticipate MacroGenics' stock price to reach $34.29 in the next twelve months. This suggests a possible upside of 82.7% from the stock's current price.
View analysts' price targets for MacroGenics or view top-rated stocks among Wall Street analysts.

Who are MacroGenics' key executives?

MacroGenics' management team includes the following people:

• Scott E. Koenig, President, Chief Executive Officer & Director
• James Karrels, Chief Financial Officer, Secretary & Senior VP
• Ezio Bonvini, Chief Scientific Officer & Senior VP-Research
• Stephen L. Eck, Chief Medical Officer & SVP-Clinical Development
• Lynn Cilinski, Treasurer, Vice President & Controller

What is Scott Koenig's approval rating as MacroGenics' CEO?

12 employees have rated MacroGenics CEO Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among MacroGenics' employees.

Who are some of MacroGenics' key competitors?

Some companies that are related to MacroGenics include Allakos (ALLK), Arvinas (ARVN), Ionis Pharmaceuticals (IONS), Karuna Therapeutics (KRTX), Apellis Pharmaceuticals (APLS), 23andMe (ME), Alkermes (ALKS), Arena Pharmaceuticals (ARNA), Intra-Cellular Therapies (ITCI), Zentalis Pharmaceuticals (ZNTL), Insmed (INSM), TG Therapeutics (TGTX), Cytokinetics (CYTK), Arcus Biosciences (RCUS) and Galapagos (GLPG).
View all of MGNX's competitors.

What other stocks do shareholders of MacroGenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Intra-Cellular Therapies (ITCI), TG Therapeutics (TGTX) and Bausch Health Companies (BHC).

What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

Who are MacroGenics' major shareholders?

MacroGenics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bellevue Group AG (13.95%), BlackRock Inc. (8.75%), Wasatch Advisors Inc. (7.05%), RTW Investments LP (6.49%), Victory Capital Management Inc. (3.22%) and Dimensional Fund Advisors LP (1.99%). Company insiders that own MacroGenics stock include Eric Blasius Risser, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Kenneth Galbraith, Target N V Biotech and Thomas Spitznagel.
View institutional ownership trends for MacroGenics.

Which major investors are selling MacroGenics stock?

MGNX stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, BlackRock Inc., Morgan Stanley, Two Sigma Advisers LP, Panagora Asset Management Inc., Opaleye Management Inc., Dimensional Fund Advisors LP, and Citigroup Inc.. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, and Thomas Spitznagel.
View insider buying and selling activity for MacroGenics or view top insider-selling stocks.

Which major investors are buying MacroGenics stock?

MGNX stock was acquired by a variety of institutional investors in the last quarter, including RTW Investments LP, Bellevue Group AG, Point72 Asset Management L.P., Victory Capital Management Inc., Wasatch Advisors Inc., Rock Springs Capital Management LP, Integral Health Asset Management LLC, and Goldman Sachs Group Inc..
View insider buying and selling activity for MacroGenics or or view top insider-buying stocks.

How do I buy shares of MacroGenics?

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MacroGenics' stock price today?

One share of MGNX stock can currently be purchased for approximately $18.77.

How much money does MacroGenics make?

MacroGenics has a market capitalization of $1.15 billion and generates $104.88 million in revenue each year. The biopharmaceutical company earns $-129.74 million in net income (profit) each year or ($2.40) on an earnings per share basis.

How many employees does MacroGenics have?

MacroGenics employs 370 workers across the globe.

What is MacroGenics' official website?

The official website for MacroGenics is www.macrogenics.com.

Where are MacroGenics' headquarters?

MacroGenics is headquartered at 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at (301) 251-5172, via email at [email protected], or via fax at 301-251-5321.